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It is essential to have a simple, quick and sensitive method for the detection and quantiﬁcation of botu-
linum neurotoxins, the most toxic substances and the causative agents of botulism. Type C botulinum
neurotoxin (BoNT/C) represents one of the seven members of distinctive BoNT serotypes (A to G) that
cause botulism in animals and avians. Here we report the development of optimized peptide substrates
for improving the detection of BoNT/C and /CD mosaic toxins using an Endopep-MS assay, a mass spec-
trometry-based method that is able to rapidly and sensitively detect and differentiate all types of BoNTs
by extracting the toxin with speciﬁc antibodies and detecting the unique cleavage products of peptide
substrates. Based on the sequence of a short SNAP-25 peptide, we conducted optimization through a
comprehensive process including length determination, terminal modiﬁcation, single and multiple amino
acid residue substitution, and incorporation of unnatural amino acid residues. Our data demonstrate that
an optimal peptide provides a more than 200-fold improvement over the substrate currently used in the
Endopep-MS assay for the detection of BoNT/C1 and /CD mosaic. Using the new substrate in a four-hour
cleavage reaction, the limit of detection for the BoNT/C1 complex spiked in buffer, serum and milk
samples was determined to be 0.5, 0.5 and 1 mouseLD50/mL, respectively, representing a similar or higher
sensitivity than that obtained by traditional mouse bioassay.
Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/4.0/).1. Introduction
Botulinum neurotoxins (BoNTs) produced by some species of
the genus Clostridium can cause a life-threatening disease, botu-
lism, in humans and animals through blocking the transmission
of acetylcholine at the neuromuscular junction leading to ﬂaccid
paralysis.1 There are seven structurally related serotypes of
BoNTs; type A, B, E, and F cause human botulism, type C, D, and
E are responsible for animal and avian botulism, and type G was
isolated from soil but has not been known to cause a natural case
of botulism.2 The BoNTs belong to a family of zinc-dependent met-
alloproteases which consists of two polypeptide chains linked
through a disulﬁde bond. The heavy chain of approximately
100 kDa is responsible for binding and entering targeted cells.
The 50 kDa light chain functions as an endoprotease domain which
cleaves neuronal proteins involved in exocytosis of neurotransmit-
ters, such as SNAP-25, synaptobrevin (VAMP2) and syntaxin, and
each BoNT has a distinct cleavage site on these SNARE substrates.3BoNT/C1 is a common term for the type C botulinum neurotoxin
which will be referred as BoNT/C throughout this manuscript.
BoNT/C is different from the botulinum C2 toxin, which is not a
neurotoxin but is a toxic protein that catalyzes the ADP-ribosyla-
tion of G-actin.4 Some Clostridium botulinum strains produce
neurotoxins as mosaic isoforms of BoNT/C and /D known as C/D
or D/C mosaics. The BoNT C/D and D/C mosaics are composed of
a chimeric structure of type C and D neurotoxins where the ﬁrst
letter designates the light chain activity and the second the heavy
chain speciﬁcity.5 It has been reported that BoNT/CD and /DC
mosaics are associated with avian and bovine botulism.6–9 Unlike
other BoNTs that only target one native substrate, either
SNAP-25 or VAMP2, BoNT/C and BoNT/CD are able to hydrolyze
two substrates: SNAP-2510,11 and syntaxin.12,13 The BoNT/C
cleavage site on SNAP-25 is Arg198-Ala199, just one residue
towards the C-terminus from the scission bond for BoNT/A on this
substrate. The hydrolysis of syntaxin by the light chain of BoNT/C
and /CD occurs at Lys253-Ala254 near the carboxyl-terminal
region of the substrate. Although BoNT/C was reported to be
almost as active as BoNT/A in an in vivo assay, the in vitro cleavage
efﬁciency of SNAP-25 by BoNT/C, was demonstrated to be much
lower than that by BoNT/A.14
3668 D. Wang et al. / Bioorg. Med. Chem. 23 (2015) 3667–3673For rapid and sensitive detection of botulinum neurotoxins,
many in vitro endopeptidase activity assays based on BoNT’s
intrinsic enzymatic function have been developed as alternatives
to the mouse bioassay. The mouse bioassay is the historic standard
method. It requires the use of many laboratory animals and is
relatively slow.15 Peptides derived from the native substrates have
been used as substrates for endopeptidase methods and the
presence of BoNT is determined through the detection of cleavage
products using various detection platforms. A previous report has
shown that a long peptide, SNAP-25(93–206), can be cleaved by
BoNT/C as efﬁciently as full-length SNAP-25.14 Short versions of a
SNAP-25 peptide have also been used as substrates to determine
the proteolytic activity of BoNT/C in endopeptidase immunoassays
and HPLC assays.16,17 In addition to SNAP-25, peptides derived
from syntaxin (232–266) have also been utilized as BoNT/C
substrates in an endopeptidase assay.17
A mass spectrometry-based Endopep-MS assay which detected
all seven BoNT serotypes was developed in our laboratory utilizing
modiﬁed SNAP-25 or syntaxin peptide substrates for the determi-
nation of BoNT/C and BoNT/CD cleavage activities.8,18,19 BoNT/C
detection by this strategy was not very sensitive in relation to
the mouse bioassay and needed improvements. In this Letter, we
describe the development of novel peptide substrates for improv-
ing sensitivity of the Endopep-MS assay for the sensitive detection
of BoNT/C and /CD toxins.2. Materials and methods
2.1. Materials
All chemicals were obtained from Sigma–Aldrich (St. Louis, MO)
except where indicated otherwise. Fmoc-amino acid derivatives
and peptide synthesis reagents were purchased from EMD
Chemicals, Inc. (Gibbstown, NJ) or Protein Technologies (Tucson,
AZ). Isotopically labeled Fmoc-amino acid derivatives were
purchased from Cambridge Isotope Laboratories (Tewksbury,
MA). Botulinum type C toxin complex was obtained from
Metabiologics (Madison, WI). The speciﬁc activity determined by
mouse bioassay and protein concentration of the toxin was pro-
vided by the manufacturer. The culture supernatant of BoNT/CD
mosaic was provided by Theresa Smith of the United States Army
Medical Research Institute of Infectious Diseases (USAMRIID).
Monoclonal antibody 8DC1.2 was provided by Dr. James Marks at
the University of California, San Francisco. Streptavidin coated
Dyna-beads were purchased from Invitrogen (Lake Success, NY).
Botulinum neurotoxin is a highly toxic substance and therefore
requires appropriate safety measures. All neurotoxins were han-
dled by trained personnel in a level 2 biosafety cabinet equipped
with HEPA ﬁlters and all standard safety handling and decontam-
ination procedures were followed. Serum was collected from
anonymous donors and was purchased from the Interstate
Bloodbank. No demographic information was obtained.2.2. Peptide synthesis
All peptides were prepared in house by a solid phase peptide
synthesis method using Fmoc chemistry on a Liberty microwave
peptide synthesizer (CEM, Matthews, NC, USA) or Symphony X
peptide synthesizer (Protein Technologies, Tucson, AZ, USA).
Peptides were cleaved and deblocked using a reagent mixture of
94% triﬂuoroacetic acid/2.5% water/2.5% 1,2-ethanedithiol/1% tri-
isopropyl silane and puriﬁed by reversed-phase HPLC using a
0.1% TFA water/acetonitrile gradient. Correct peptide structures
were conﬁrmed by MALDI mass spectrometry. All peptides weredissolved in deionized water as a 1 mM stock solution and were
stored at 70 C until further use.
2.3. Endopep-MS assay
In-solution or on-bead Endopep-MS assays were carried out as
previously described.20 In brief, the reaction was conducted in a
20 lL reaction volume containing 0.1 mM peptide substrate,
10 lM ZnCl2, 1 mg/mL BSA, 10 mM dithiothreitol, and 200 mM
HEPES buffer (pH 7.4) at 42 C for 4 h or as indicated in the text.
For the in-solution assays without antibody-coated beads, various
concentrations of BoNT/C (as indicated in Section 3) were directly
added into the reaction mixture. For samples including complex
matrices and BoNT/CD mosaic supernatant, the toxin spiked in
matrix was ﬁrst puriﬁed by a BoNT/D speciﬁc antibody and immo-
bilized on streptavidin beads, followed by an activity assay as
described.20
After completion of the timed reaction, 2 lL of the supernatant
was mixed with 16 lL of a-cyano-4-hydroxy cinnamic acid at
5 mg/mL in 50% acetonitrile/0.1% TFA/1 mM ammonium citrate;
2 lL of a 0.5 or 1 lM internal standard peptide (isotope labeled
peptides resembling the sequence of either the C- or N-terminal
cleavage product of some peptide substrates during optimization
process) was added to the solution if the peptide was used. The
formation of cleavage products was measured as the ratio of the
isotope cluster areas of the MS peak of the cleavage product versus
an internal standard. The data were usually an average of three
experiments. CV values for the samples were typically below 20%.
2.4. MS detection
Each sample was spotted in triplicate on a MALDI plate and ana-
lyzed on a 5800 MALDI-TOF-TOF MS instrument (Applied
Biosystems, Framingham, MA). Mass spectra of each spot were
obtained by scanning from 800 to 4000 m/z in MS-positive ion
reﬂector mode. The instrument uses a Nd-YAG laser at 355 nm,
and each spectrum is an average of 2400 laser shots.
3. Results and discussion
3.1. Selection of an appropriate template as a BoNT/C substrate
The principle of the mass spectrometry-based Endopep-MS
assay includes the detection of cleavage products hydrolyzed from
a peptide substrate by BoNT by matrix-assisted laser desorption/
ionization (MALDI) or electrospray ionization (ESI) mass spectrom-
etry. The focus of this work will be on the detection by MALDI TOF
MS. Improvements in assay sensitivity directly rely on elevated
peak intensities of the cleavage peptide fragments arising from
either increased hydrolysis efﬁciency or ampliﬁed ionization efﬁ-
ciency of the products or both effects combined. Therefore, the
only parameter we focused on in this study was the change in
the intensity of the cleavage product peak in a mass spectrum
resulting from optimization of the structure of a BoNT/C peptide
substrate, regardless if the change was caused by creation of a bet-
ter substrate (related to hydrolysis), or a better cleavage product
(related to ionization by MALDI) or a combination of both effects.
In order to determine an appropriate sequence template as a
starting point for the optimization of BoNT/C substrate, three
synthetic peptides were initially examined (Table 1). Pep-1 was
derived from SNAP-25 with some terminal and internal modiﬁca-
tions. This is a dual substrate of BoNT/A and BoNT/C used in the
Endopep-MS activity assay.8,18,19 Pep-2 is among some syntaxin
peptides prepared in our laboratory in a previous investigation
of potential BoNT/C substrates (unpublished data). Pep-3 is a
Table 1
Cleavage of peptide substrates by BoNT/Ca
Peptide # Sequence Area ratio
CT-product NT-product
Pep-1b Biot-KGSNRTRIDEANQRATRMLGGK-Biot 0.7 0.5
Pep-2 YVERAVSDTKKAVKYQSKARRKKIMII 0.2 0.7
Pep-3 Ac-RIDEANQRATKMLGR-NH2 2.3 1.5
Pep-4 Ac-RIDEANQRATKMRRR-NH2 0.2 0.1
Pep-5 Ac-RIDEANQRATKXRRR-NH2 0.0 0.0
Pep-6 Ac-RIDEANQRATKMLGRRR-NH2 2.6 1.7
Pep-7 Ac-TRIDEANQRATKMLGRRR-NH2 2.5 2.0
Pep-8 Ac-KTRIDEANQRATKMLGRRR-NH2 3.1 1.5
Pep-9 Ac-NKTRIDEANQRATKMLGRRR-NH2 4.5 2.8
Pep-10 Ac-SNKTRIDEANQRATKMLGRRR-NH2 2.6 1.1
a Cleavage reaction: 20 lL reaction solutions including 500 mouseLD50 toxin, 100 lM peptide and other components 42 C
for 4 h.
b The Pep-1 is the BoNT/C substrate originally used in the Endopep-MS assay. Biot represent biotination modiﬁer.
Underlined residues represent BoNT/C cleavage site.
Figure 1. MALDI mass spectra for the detection of BoNT/C using Pep-2 without (A)
and with (B) 1000 mouseLD50 toxin added, and using Pep-3 without (C) and with
(D) toxin added. The peaks of doubly charged substrate ions and both N-terminal
and C-terminal cleavage products were labeled.
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addition of Arg to its C-terminus and modiﬁcations at both C- and
N-termini. This peptide was found to be one of the promising
candidates as a BoNT/A substrate in a previous study, but was
not examined for BoNT/C hydrolysis (unpublished data).
Assessment of these peptides for BoNT/C activity showed the
absence of any fragment peaks in control samples (Fig. 1A and C)
but the presence of pairs of new peaks in reaction samples
(Fig. 1B and D), showing that Pep-2 and Pep-3, similar to Pep-1,
are effective substrates of BoNT/C in the Endopep-MS activity
assay. A comparison of the peak area ratios of the cleavage prod-
ucts versus the internal standard (Table 1) indicates that Pep-3
yielded more C-terminal cleavage product (CT-product) and
N-terminal product (NT-product) than the currently used
substrate, Pep-1, and thus it was selected as a SNAP-25 peptide
template for further improvement. In parallel, we also attempted
to develop a better syntaxin sequence-based substrate using
Pep-2 as a template. However, the development procedure of this
type substrate is not included in the present discussion, since the
ﬁnal optimal peptide from the template showed less ideal results
than the optimized SNAP-25 sequence-based peptides.
The ionization efﬁciency of a peptide can sometimes be pro-
moted in positive ion mode mass spectrometry, if it contains basic
amino acid residues such as lysine and arginine in its sequence,
due to the high proton afﬁnity of these amino acid residues.21
For this reason, we incorporated two more arginine residues into
the Pep-3 sequence by replacing existing C-terminal leucine and
glycine to form Pep-4 as the ﬁrst optimization step, in order to
achieve better detection of the CT-product. An additional substitu-
tion of methionine with norleucine (X) was made in Pep-5 in an
attempt to avoid unwanted oxidation of this residue during the
peptide preparation and storage. Unlike Pep-4, two arginine resi-
dues were directly added in Pep-6 to the C-terminus of the tem-
plate without making any other changes to the template
sequence. Evaluation of these three new peptides demonstrated
that the replacement of LG with RR in Pep-4 led to a signiﬁcant
decrease in the detection of both CT- and NT-products (Table 1).
Because Pep-4 and Pep-3 share the same sequence in their
N-terminal cleavage parts, the 10-fold reduction in the
NT-products suggested that reduced detection of the cleavage
products from Pep-4 were caused by decreased substrate efﬁciency
of the modiﬁed peptide. By comparing Pep-5 with Pep-4, the
substitution of methionine by norleucine, a general alternate used
in peptide mutation, completely diminished the capability of the
Pep-5 as a BoNT/C substrate under the experimental conditionsused, indicating that residues at the position close to the cleavage
site (such as Leu, Gly, and Met here) are susceptible to change in
their structures. By contrast, addition of two extra arginine
residues (Pep-6) did not impact its substrate cleavage efﬁciency
but led to a slight improvement in the detection of both cleavage
products as compared to Pep-3.
Figure 2. Formation of CT-product generated from the BoNT/C cleavage of single
substituted peptides. (A) In wild type Pep-9 (Ac-N1K2T3R4I5D6E7A8N9Q10R11A12
T13K14M15L16G17R18R19R20-NH2) template (wt), the N1 was replaced with Q, D, R, G,
A, F, or V, respectively, in seven new peptides. (B) In Pep-11 (Ac-V1K2T3R4I5D6E7
A8N9Q10R11A12T13K14M15L16G17R18R19R20-NH2), Q10 was substituted with A, K, D or
N, respectively. (C) In Pep-12 (Ac-V1K2T3R4I5D6E7A8N9N10R11A12T13K14M15L16G17
R18R19R20-NH2), the N9 was changed to Q, A, D, E, or K residue, respectively.
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assay sensitivity. Pep-7 through Pep-10 was constructed by adding
a single amino acid residue each time to the template, based on the
SNAP-25 sequence, to the N-terminus of Pep-6 (Table 1). While a
similar level of CT-product was generated from Pep-7 (Peak area
ratio: 2.6) and Pep-10 (2.6) compared to that for Pep-6 (2.6), signif-
icant elevation of the CT-product was observed from the cleavage
of Pep-8 (3.1) and Pep-9 (4.5). An almost two-fold increase in both
CT-product and NT-product from the cleavage of Pep-9 revealed
that the string of NKT in the N-terminus of Pep-9 improved its
hydrolysis efﬁciency as a BoNT/C substrate and the ionization efﬁ-
ciency of its NT-product.
3.2. Optimization by single and multiple amino acid residue
substitution
Using Pep-9 as a new template, the effect of substitutions of
some residues located around the cleavage site and the peptide
termini were investigated. The N-terminal asparagine (N1) was
replaced with the residues of various properties (Fig. 2A). By com-
paring the formation of the CT-product of these new peptides, it
was observed that the mutants of N1Q and N1D performed simi-
larly or relatively better than the wild type (Pep-9) did. By contrast,
no response was detected on a N2R mutant, indicating that the
introduction of a positive charge side chain at this position dimin-
ished the substrate capability of binding. Interestingly, replace-
ment of the N1 residue with three nonpolar residues G, A, or V,
generated a more effective substrate, where the CT-products were
more than two-fold higher than that of the original Pep-9, presum-
ably due to improved substrate–enzyme interaction. On the other
hand, reduced CT-product formation from the N1F mutant sug-
gests that a bulky aromatic ring of the phenylalanine side chain,
even though nonpolar, might disfavor the substrate–enzyme inter-
action. Consequently the N1V mutant (Pep-11) was subjected to
further improvement; where the residue Q10, immediately adja-
cent to the scission bond residue R11 was exchanged to A, K, D
and N. As shown in Figure 2B, both positive and negative charges
at this position completely destroyed the substrate activity of the
modiﬁed peptides, while the nonpolar and small sized alanine
was tolerated and did not enhance or diminish the peptide cleav-
age. By contrast, a structurally minor substitution (Pep-12), Q10N
with one methyl group removed in this side chain, surprisingly
resulted in a dramatic improvement where the production of the
cleavage product increased ﬁve-fold. These results underline the
importance of the amino acid residues at or around the cleavage
site, where a subtle change in structure can make an enormous dif-
ference in peptide activity. Figure 2C displays the result from the
peptides derived from substitutions of N9 in Pep-12 by the amino
acids Q, A, D, E, or K. Unlike previous modiﬁcations at position
10, all peptides with substitution at position 9 underwent only
moderate changes in cleavage efﬁciency. The Pep-13 bearing the
N9Q mutation was then selected as a new template, due to its
slight improvement on assay sensitivity.
To examine the contribution and potential of other amino acid
residues in Pep-13 for the detection of the cleavage products, an
Ala-scanning peptide library was prepared where each non-alanine
residue (not modiﬁed previously) was sequentially substituted by
alanine. In addition, glycine was used to substitute each of the
two alanine residues to form two more peptides. Also, the cleav-
age-site forming arginine was replaced by lysine rather than ala-
nine to retain the positive charge property at this position,
considering that other non-trivial changes in this position might
negatively alter the function of a peptide substrate. Moreover,
two more peptides were prepared by either removing the acetyl
group on the N-terminus or by omitting C-terminal amidation in
Pep-13. Only the CT-products were compared since the CT-productpeaks cleaved from all peptides tested were higher than that of its
N-terminal counterpart. Figure 3 displayed the response of these
single-mutated peptides under the cleavage of BoNT/C and the
results were grouped into ﬁve categories in terms of relative CT-
product measurement. The level of the cleavage products declined
more than 80% when either of the only two acidic residues, D6 and
E7, were substituted by alanine, implying that negative charges at
these positions are necessary to maintain the high hydrolysis efﬁ-
ciency of the substrate (Pep-13). Similar impact was detected
when the original alanine residues, A8 and A12, were switched to
the smaller glycine residues, suggesting the importance of retain-
ing at least the side chain of alanine or maintaining a chiral conﬁg-
uration at these positions. Reduced hydrolysis (30–50%) was also
observed on peptides where either of the terminal protection
groups were removed, indicating that terminal acetylation and
amidation, which was originally designed to make the peptide
Table 2
Effect of single or multiple substitutions on the cleavage efﬁciency of modiﬁed
peptides by BoNT/C*
* Red letters represent substituted residues. X: norleucine; O: ornithine.
Figure 3. Cleavage efﬁciency of single substituted Pep-13 hydrolyzed by
100 mouseLD50 BoNT/C. The top row is the primary amino acid sequence of Pep-
13. The bottom row represents the point mutated peptide-13. These peptides
include two mutants that lack either N-terminal acetylation or C-terminal
amidation. Underlined are the residues at the BoNT/C cleavage site.
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hydrolysis of Pep-13 by the BoNT/C.
While some mutations or modiﬁcations described above led to
a reduced cleavage response, others either improved or did not
alter the cleavage of the modiﬁed peptides. The alanine substitu-
tion of the isoleucine residue at position 5 and the glycine residue
at position 11 led to a 70% and 30% improvement, respectively. This
demonstrated that just small changes in the size, but not the
polarity, of the side chains of these two residues improve the
BoNT/C hydrolysis of these substituted peptides. The most striking
improvement occurred when the cleavage-site residue arginine
was changed to lysine, a similar residue that possesses a positive
charge. The R11K substituted peptide, Pep-14, resulted in a 2.6-fold
enhancement in the formation of the CT-product, therefore it was
selected as a new template for further optimization.
The next reﬁnement step was to manipulate the sequence of
Pep-14 with multiple substitutions in an attempt to gain additional
improvements. Although several single-substitutions displayed
improved results, simply placing together these substitutions into
a single sequence may not guarantee an augmented effect. Any
single substitution on the peptide may or may not alter its confor-
mation and affect its intra- and/or inter-molecular interactions.
Therefore, the introduction of a speciﬁc additional substitution(s)
to a singly-substituted peptide (with positive results) may not pro-
vide the same positive beneﬁt on a new doubly or multiply-modi-
ﬁed one; as it did on the original, non-substituted peptide. For this
reason, we applied a strategy that screens selected residues from
C- to N-terminus of Pep-14 with various substitutions, based on
the information obtained from the single-substitution study
described above. Once a better residue is determined at a speciﬁc
position, the residue becomes a ﬁxed substitution incorporated
into the sequence for the next screening. Table 2 lists multiple-
substituted peptides obtained following this approach, where red
letters represent the newly incorporated residues on the sequence
of Pep-14. Starting from the glycine residue at position 17, the
effect of G17A in Pep-15 gave rise to a similar increase (from 1.0
to 1.3) on the CT-product level as the same mutation on Pep-13.
Extension of the nonpolar side chain of isoleucine at position 17
in Pep-16 resulted in more CT-product detected; presumably due
to enhanced hydrophobic–hydrophobic interaction between
enzyme and substrate or increased ionization efﬁciency of the
cleavage product. This effect, however, was diminished by an even
larger phenylalanine group in Pep-17. As a result, the Ile residue
was ﬁxed in this position for further optimization. Ala-scanning
data indicated that the original residues in the region of T13–L16
were important, hence only conservative substitutions were con-
ducted on these positions. L16G caused a slight improvement
(2.3 in Pep-16 vs 2.7 in Pep-18), leading to a permanent placement
of glycine at this position. Added advantages of this replacementinclude potentially reducing hydrophobicity of a peptide, which
may decrease the difﬁculty of peptide synthesis, and improve pep-
tide solubility in enzymatic reaction solutions. By contrast to L16G,
replacement of L16 with a positively charged K or a negatively
charged D yielded inferior substrates (Pep-19 and Pep-20), under-
scoring the signiﬁcance that a conservative substitution is required
in this position. For the residue at the position 14, however, even a
substitution with similar properties, K14R, gave rise to a signiﬁcant
reduction in the cleavage product (Pep-21 vs Pep-18). Meanwhile,
the amount of the product (5.2) doubled once the T13 was substi-
tuted with serine (Pep-22 vs Pep-18). Interestingly, this signiﬁcant
improvement could be negated by combining the T13S and K14R
substitutions (Pep-21). This effect was not unexpected, since the
residues at these positions are very close to the cleavage site of
the BoNT/C substrate, and may directly participate in the hydroly-
sis process and are therefore more susceptible to any changes.
The residue at position 5 was the next one to be considered, due
to increased CT-product from an I5A substitution. Various amino
acids of different side chain properties were tested to replace iso-
leucine at this position (Pep-24 to Pep-29), however, reduced per-
formance or inferior results were observed for all of these mutants.
Although the I5A substitution on the original Pep-13 resulted in an
elevated cleavage product, this mutation (Pep-24) derived from the
sequence of Pep-22 (which included four newly replaced residues)
led to the detection of fewer CT-products (3.9 for Pep-24 vs 5.2
for Pep-22); underscoring the difference between single- and
Figure 4. Structure of the three positively charged amino acids: arginine, lysine and
ornithine.
Table 3
Cleavage of the current (Pep-1) and newly developed (Pep-39) substrates hydrolyzed
by BoNT/C and /CD mosaic*
BoNT Area ratio (CT-product)
Pep-1 Pep-39
C1 0.3 70.6
C/D mosaic 0.2 41.3
* BoNT/C (100 mouseLD50) was directly added into the reaction solution. BoNT/
CD mosaic was puriﬁed from 2 lL culture supernatant spiked PBST buffer via
antibody-beads followed by on-beads reaction. Experiment performed in triplicate.
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due in position 4 was replaced by a different type of amino acid, all
peptides (Pep-30 to Pep-34) displayed better performance as
BoNT/C substrates compared to Pep-22, demonstrating the ﬂexible
requirements of the amino acid residues in this position. With
Pep-34 as a new template, conservative substitution of threonine
in position 3 with serine (Pep-35) or tyrosine (Pep-36), further
improved the yield of the cleavage products (9.6 and 10.1) com-
pared to the template (8.6). By contrast, lower hydrolysis products
resulted from another conservative amino acid change in position
2 (K2R) in Pep-37 (7.2) and this reduction was not overcome by a
double mutation of K2R and T3S in Pep-38 (7.3).
Given the success of the substitution of the original cleavage
site residue, R11, with another positively charged lysine residueFigure 5. (Left) product response from the cleavage of Pep-39 by BoNT/C of various c
R2 = 0.998). LODs were determined to be 0.5, 0.5 and 1.0 mouseLD50/mL for buffer, serum
the cleavage reactions without (upper) and with (lower) adding toxin.in Pep-14; we then explored the effect of replacing two lysine resi-
dues (K11 and K14) in Pep-36, the best BoNT/C substrate up to now,
with ornithine (represented by O). Ornithine is a non-essential
amino acid derived from the breakdown of arginine during the
citric acid cycle and has a structure similar to lysine but one
methyl group shorter than the latter (Fig. 4). When K14, two resi-
dues downstream from the cleavage site, was changed to ornithine
(Pep-39), a remarkable enhancement (2.6 fold) was obtained
(Table 2). In addition, a moderate improvement (from 10.1 to
12.3) was detected from K11O substitution (Pep-40) and almost
two-fold increase in CT-product detection (from 10.1 to 19.2)
was achieved with K11O/K14O combination (Pep-41). Because
the chemical properties of lysine and ornithine are similar, these
improvements were unlikely to result from the elevated ionization
efﬁciency of the CT-product during mass spectrometric acquisition.
A more reasonable explanation could be that the positively
charged residue in position 14 is directly involved in an enzyme–
substrate interaction(s) or cleavage process, and a short side chain
of ornithine further enhances such interaction(s). The elucidation
of the mechanism that underlies this phenomenon will require
additional biochemical and biophysical studies, such as crystallog-
raphy analysis.
3.3. Comparison of the optimal peptide with the original
substrate and its application in biological sample matrices
The optimal peptide, Pep-39, was then compared to Pep-1, the
originally-used substrate described in the Endopep-MS assay for
the detection of type C botulinum neurotoxin.18 The substrates
were tested with two major forms of toxins: one is BoNT/C as a
complex with neurotoxin-associated proteins, and another one is
the C/D mosaic containing an enzymatic light chain very similar
to BoNT/C and a heavy chain similar to BoNT/D. As shown in
Table 3, the area ratio of CT-product versus the internal standard
was measured as 0.3 from Pep-1 compared to the value of 70.6
from Pep-39 cleaved by BoNT/C under identical experimental con-
ditions. The product peak increased from 0.2 for Pep-1 to 41.3 for
Pep-39 with the cleavage by C/D mosaic. Both results represent
more than 200-fold increase in the detection of the cleavage pro-
duct, demonstrating a dramatic enhancement in the sensitivity of
the Endopep-MS assay. Figure 5 displays the assay results for var-
ious concentrations of BoNT/C spiked in reaction buffer and two
complex matrices, serum and milk. Good linearity within the test
range of toxin concentrations was obtained and the limit of detec-
tion of 0.5, 0.5 and 1.0 mouseLD50 (1 pg/mL or 5.5 attomole/mL)
toxin in buffer, serum and milk was accomplished after a 4 houroncentrations spiked in buffer (s, R2 = 0.999), serum (h, R2 = 0.999) and milk (4,
and milk, respectively. Reaction condition: 37 C, 4 h. (Right) typical mass spectra of
D. Wang et al. / Bioorg. Med. Chem. 23 (2015) 3667–3673 3673cleavage reaction (Fig. 5) in contrast to the LOD of 50 mouseLD50 of
the toxin in buffer using the old substrate under the same assay
conditions (data not shown).
4. Conclusion
Novel peptide substrates were developed for the mass spec-
trometry-based Endopep-MS assay for the detection of type C
botulinum neurotoxin. Based on the sequence of a small, modiﬁed,
SNAP-25 peptide, we conducted optimization through a compre-
hensive process including length determination, terminal mod-
iﬁcation, single and multiple amino acid residue substitution, and
incorporation of unnatural amino acid residues. Our data demon-
strate that an optimal peptide substrate (Ac-VKYNIDEAQNKASO
MGIRRR-NH2, O = ornithine) provided more than 200-fold
improvement over the original substrate used for the detection
of BoNT/C and /CD mosaic. The sensitivity for the detection of
BoNT/C using the Endopep-MS assay was signiﬁcantly increased.
The new peptide substrate allows the accomplishment of a similar
or higher sensitivity than that obtained using the traditional mouse
bioassay, however the Endopep-MS assay is more rapid, requiring
only a four hour reaction time. The limit of detection for the
BoNT/C complexes spiked in buffer, serum and milk samples was
determined to be 0.5, 0.5 and 1 mouseLD50/mL, respectively.
5. Disclaimer
The ﬁndings and conclusions in this Letter are those of the
authors and do not necessarily represent the ofﬁcial position of
the Centers for Disease Control and Prevention.References and notes
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